We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial
News

Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial

Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial
News

Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Calando Pharmaceuticals Doses First Patient in siRNA Phase I Clinical Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation announced that the first patient has successfully completed the first dosing cycle (four doses over two weeks) of CALAA-01 in the first clinical trial using systemically-delivered siRNA to treat cancer.

CALAA-01 is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase - a clinically-validated cancer target - formulated with Calando’s proprietary RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymer delivery system.

The first patient was enrolled and dosed at South Texas Accelerated Research Therapeutics (START) in San Antonio, Texas.

This open-label, dose-escalation Phase I study in patients with solid tumors which are refractory to standard-of-care therapies is being conducted at the UCLA Jonsson Cancer Center (UCLA) in Los Angeles, California, and at South Texas Accelerated Research Therapeutics (START) in San Antonio, Texas. It is being led by Drs. Antoni Ribas (UCLA) and Anthony Tolcher (START).

“The initiation of this Phase I clinical trial of CALAA-01 is a hallmark for Calando and for the field of RNAi therapeutics,” said Calando CSO for siRNA delivery, Jeremy Heidel, Ph.D.

Heidel added, “We look forward to the continued treatment of this patient and subsequent patients and the establishment of safety and efficacy profiles for CALAA-01 in humans.”

Advertisement